Systemic lupus erythematosus and antiphospholipid syndrome in children and adolescents

Current Opinion in Rheumatology

Volumn 13, Issue 5, 2001, Pages 415-421

  Lee, Tzielan ^a   Von Scheven, Emily ^b   Sandborg, Christy ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID;

ADOLESCENT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CHILD; CHILDHOOD DISEASE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; MORBIDITY; NEUROPSYCHIATRY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VIRUS INFECTION;

ADOLESCENT; ANTIPHOSPHOLIPID SYNDROME; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0034809608     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200109000-00013     Document Type: Review

References (98)

1. Adult- and childhood-onset systemic lupus erythematosus: A comparison of onset, clinical features, serology, and outcome
2. Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus
3. Childhood-onset systemic lupus erythematosus: A comparative study of African Americans and Latin Americans
4. Clinical features of Japanese children and adolescents with systemic lupus erythematosus: Results of 1980-1994 survey
5. Lupus nephritis
6. Increasing incidence of childhood class V lupus nephritis
7. Lupus nephritis in children: Prognostic significance of clinicopathological findings
8. Systemic lupus erythematosus
9. Distal tubular dysfunction in lupus nephritis of childhood and adolescence
10. Pulmonary involvement in juvenile systemic lupus erythematosus: A study on lung function in patients asymptomatic for respiratory disease
11. Pulmonary manifestations of rheumatic diseases
12. Primary and secondary pulmonary hypertension in systemic lupus erythematosus
13. Systemic lupus erythematosus: A model for atherogenesis?
14. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus
15. Epidemiology of cardiovascular disease in systemic lupus erythematosus
16. Fatal myocardial infarction in an 8-year-old girl with systemic lupus erythematosus, Raynaud's phenomenon, and secondary antiphospholipid antibody syndrome
17. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study
18. Autoimmunity in atherosclerosis: Lessons from experimental models
19. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus
20. Dyslipoproteinemia in pediatric systemic lupus erythematosus
21. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs
22. Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus
23. Premature atherosclerosis in systemic lupus erythematosus
24. Neurologic symptoms in children with systemic lupus erythematosus
25. Neurologic manifestations of pediatric systemic lupus erythematosus
26. Neurologic characteristics of childhood lupus erythematosus
27. Evaluation of predictive factors for neurocognitive dysfunction in patients with inactive systemic lupus erythematosus
28. Risk factors for central nervous system involvement in systemic lupus erythematosus
29. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus
30. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement
31. Soluble L-selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus
32. Central nervous system involvement in systemic lupus erythematosus: Cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations
33. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging
34. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus
35. Prevalence of cognitive impairment in systemic lupus erythematosus
36. Cognitive impairment in patients with systemic lupus erythematosus
37. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus
38. Screening for autoimmune markers is unnecessary during follow-up of adults with autoimmune thrombocytopenic purpura and no autoimmune markers at onset
39. Intracranial hemorrhage in children with immune thrombocytopenic purpura
40. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
41. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial
42. Treatment of lupus nephritis
43. Efficacy of mycophenorate mofetil in patients with diffuse proliferative lupus nephritis
44. Treatment of systemic lupus erythematosus with mycophenolate mofetil
45. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy
46. The treatment of lupus with cyclosporin A
47. Double-blind, randomized, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus
48. Damage in systemic lupus erythematosus and its association with corticosteroids
49. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus
50. Glucocorticoid effects on statural growth
51. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus
52. Monoclonal antibodies and other biologic therapies
53. Treatment of systemic lupus erythematosus with LJP 394
54. Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus
55. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study
56. Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus
57. Prothrombinase activity of human platelets is inhibited by beta 2- glycoprotein-l
58. beta 2-glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway
59. Prevalence of anticardiolipin antibodies in juvenile chronic arthritis
60. Preoperative history and coagulation screening in children undergoing tonsillectomy
61. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
62. Primary antiphospholipid syndrome: A report of two pediatric cases
63. Classification of an intermediate group of patients with antiphospholipid syndrome and lupus-like disease: Primary or secondary antiphospholipid syndrome?
64. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia
65. Prothrombotic disorders and ischemic stroke in children
66. Cerebral vein thrombosis in childhood systemic lupus erythematosus
67. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood
68. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood
69. Lack of association between antiphospholipid antibodies and migraine in children
70. Anticardiolipin antibodies in pediatric systemic lupus erythematosus
71. Budd-Chiari syndrome associated with antiphospholipid antibodies in a child: Report of a case and review of the literature
72. Anticoagulant proteins in childhood venous and arterial thrombosis: A review
73. Small vessel thrombosis without major thrombotic events in systemic lupus erythematosus patients with antiphospholipid syndrome
74. Anticardiolipin syndrome in childhood: A report of two cases
75. Venous thrombosis associated with lupus anticoagulant and anticardiolipin antibodies
76. Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome
77. Childhood adrenal insufficiency, chorea, and antiphospholipid antibodies
78. Asymptomatic superior vena cava thrombosis and pulmonary embolism in an adolescent with SLE and antiphospholipid antibodies
79. The antiphospholipid symdrome in a teenage with miscarriages, thromboses, and diabetes mellitus
80. Systemic lupus erythematosus in child with autoimmune thrombocytopenic purpura and circulating lupus anticoagulant
81. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection
82. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: Characterization in relation to antiphospholipid syndrome
83. Specificity of anti-phospholipid antibodies in infectious mononucleosis: A role for anti-cofactor protein antibodies
84. Anticardiolipin antibodies in pediatric patients with human immunodeficiency virus
85. Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus
86. Evaluation and treatment of thrombosis in the neonatal intensive care unit
87. Neonatal aortic thrombosis associated with the lupus anticoagulant
88. Antiphospholipid antibodies in pediatric systemic lupus erythematosus
89. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome
90. The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus
91. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: A cross- sectional study
92. Antibodies to beta2-glycoprotein I: A potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus
93. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus
94. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: Comparison between different assays for the detection of antiphosphotipid antibodies
95. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?
96. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: Prevalence and diagnostic value for the antiphospholipid syndrome
97. Antiphospholipid antibodies in children
98. Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome